Our results demonstrate that HDAC inhibitor and PI3K inhibitor can overcome breast cancer resistance to tamoxifen through down-regulation of the PI3k/Akt/mTOR signaling pathway. This evidence concerns the gene HDAC9 and breast carcinoma.